Virpax Pharmaceuticals, Inc. stock is down -50% since 30 days ago. The next earnings date is Mar 20, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 0% of the previous 2 December’s closed higher than November.
Virpax Pharmaceuticals, Inc. develops various drug-delivery systems and drug-releasing technologies. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee. AnQlar, an anti-viral barrier to prevent or reduce the risk of viral infections in humans, including influenza and SARS-CoV-2.